Payment overview · 2025
General Payments
$223.73
11 reported records · 5 companies
Healthcare provider profile · identity verified
Timothy R Watson, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PONTOTOC, MS · NPI 1003285461
Verified facts
What the public records show
CMS Open Payments records show Timothy R Watson, FNP-C received $223.73 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.24 | 44.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.17 | 20.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.19 | 16.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.32 | 11.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.81 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.73 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $100.24 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $45.17 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 202 | 62 |
| Gabapentin | Gabapentin | 186 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 159 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 40 |
| Potassium Chloride | Potassium Chloride | 138 | 48 |
| Losartan Potassium | Losartan Potassium | 130 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 125 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 41 |
| Lisinopril | Lisinopril | 101 | 36 |
| Metformin Hcl | Metformin Hcl | 92 | 29 |
| Alprazolam | Alprazolam | 88 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 20 |
| Azithromycin | Azithromycin | 86 | 73 |
| Sertraline Hcl | Sertraline Hcl | 86 | 29 |
| Furosemide | Furosemide | 84 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 25 |
| Azelastine Hcl | Azelastine Hcl | 71 | 43 |
| Carvedilol | Carvedilol | 70 | 27 |
| Allopurinol | Allopurinol | 68 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 25 |
| Meloxicam | Meloxicam | 63 | 24 |
| Fenofibrate | Fenofibrate | 62 | 21 |
| Prednisone | Prednisone | 62 | 59 |
| Simvastatin | Simvastatin | 62 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 32 |
| Trazodone Hcl | Trazodone Hcl | 59 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Ozempic | Semaglutide | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 17 |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Famotidine | Famotidine | 45 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 18 |
| Glimepiride | Glimepiride | 43 | 17 |
| Spironolactone | Spironolactone | 42 | 17 |
| Metformin Hcl Er | Metformin Hcl | 40 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 14 |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Sucralfate | Sucralfate | 32 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 11 |
| Torsemide | Torsemide | 30 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 24 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Cephalexin | Cephalexin | 19 | 18 |
| Mupirocin | Mupirocin | 19 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Atenolol | Atenolol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.73 · 11 records | Otsuka America Pharmaceutical, Inc. | ELIQUIS, EVENITY, FARXIGA, KISUNLA, NURTEC ODT, PROLIA, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error